
The treatment of zzso zzso cell zzso zzso has been changed by the introduction of targeted zzso Consideration of individual patient factors, such as previous treatment and zzso risk, zzso according to the Memorial zzso Cancer Center zzso risk zzso can assist in ensuring that patients receive appropriate targeted zzso Available clinical evidence shows zzso to be the reference standard of care for the zzso treatment of zzso in patients at zzso or intermediate zzso risk according to zzso zzso Combined treatment with zzso plus zzso can also be considered for the zzso treatment of zzso in this zzso For the zzso treatment of zzso patients, zzso has shown benefit in a phase III study, while zzso can also be zzso For zzso treatment in zzso patients, zzso is recommended based on phase III trial results; zzso has also shown activity after failure of zzso therapy or targeted zzso As well as zzso activity, the zzso of targeted agents should be evaluated in the context of individual patients, considering factors such as zzso and zzso As our understanding of the activity of targeted agents for zzso increases, we should ensure that these agents are used appropriately to provide patients with optimal treatment zzso 

